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Abstract
Background: White adipose tissue is not only an energy storage organ; it also functions as an
endocrine organ. The coordination and integration of numerous gene expression events is required
to establish and maintain the adipocyte phenotype.
Findings:  We previously observed a 45-fold upregulation for a transcript encoding a novel
predicted transmembrane protein, Tmem182, upon brown preadipocyte to adipocyte conversion.
Here we use real-time PCR analysis to further characterize Tmem182 transcript expression in the
adipocyte lineage. Analysis across a panel of 10 murine tissues revealed highest Tmem182
transcript expression in white adipose tissues (WAT), with 10-fold to 20-fold higher levels than in
brown adipose tissue (BAT). Tmem182 transcript expression is ~3-fold upregulated in BAT of
genetically obese (ob/ob) mice vs. wild type C57BL/6. Analysis of three in vitro models of white
adipogenesis indicates markedly enriched expression of Tmem182 transcript in adipocytes vs.
preadipocytes. Compared to 3T3-L1 preadipocytes, a 157-fold higher level of Tmem182 transcript
is detected at 3 day post-induction of adipogenesis and an ~2500-fold higher level in mature 3T3-
L1 adipocytes. TNFα treatment of 3T3-L1 adipocytes resulted in a ~90% decrease in Tmem182
transcript level. As skeletal muscle and heart were also found to express Tmem182 transcript, we
assessed expression in C2C12 myogenesis and observed a ~770-fold upregulation upon conversion
of myoblasts to myocytes.
Conclusion: WAT is the most prominent site of Tmem182 transcript expression and levels of
transcript for Tmem182 are altered in adipose tissues of ob/ob mice and upon exposure of 3T3-L1
adipocytes to the proinflammatory cytokine TNFα. The dramatic upregulation of Tmem182
transcript during in vitro adipogenesis and myogenesis suggests Tmem182 may function in
intracellular pathways important in these two cell types.
Background
White adipose tissue (WAT) is the major site for storage of
excess energy and these triglyceride stores are mobilized to
meet the energy needs of the organism. Adipose tissue is
now also recognized as an endocrine organ with synthesis
and secretion of a variety of soluble factors such as leptin,
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resistin, adiponectin, retinol binding protein-4 and TNFα
[1-4]. Adipocytes make up from one-third to two-thirds of
the cell population found in adipose tissue, with endothe-
lial cells, nerve cells, macrophages, fibroblast-like intersti-
tial cells and preadipocytes, and perhaps other cell types,
comprising the remaining stromal-vascular component
[5]. Mature adipocytes form as the result of the differenti-
ation of preadipocyte precursors present in adipose tissue
[6-10]. Established preadipocyte cell lines such as 3T3-L1
[11] have been an extensively used in vitro model to define
genes central to the adipocyte phenotype [12,13]. Adipo-
genesis is accompanied by increased transcription of
genes that encode proteins key to adipocyte function, for
example lipogenesis, lipolysis, lipid transport, and hor-
mone responsiveness [7,14,15]. In vitro and in vivo studies
have uncovered a pivotal role for peroxisome proliferator-
activated receptor γ (PPARγ), a member of the ligand-acti-
vated steroid hormone receptor family, in the adipogenic
program [8,10,16-19]. Studies have also illustrated the
important contributions of the CCAAT/enhancer-binding
proteins (C/EBPs) and other transcriptional signals to adi-
pogenesis [8,10,20].
Methods
Culture of cell lines and adipogenic conversion for 3T3-
L1, ScAP-23 and wt-BAT, for the fractionation of adipose
tissues, and for culture and differentiation of murine
preadipocytes from subcutaneous (SC) WAT was as
described [21,22]. C2C12 cells were maintained and pas-
saged as subconfluent cultures in DMEM with10% FBS.
For differentiation, cultures at 70% confluence were
switched to DMEM with 2% horse serum and 10 μg/ml
insulin, and were cultured under these conditions for 7
days. For treatment of 3T3-L1 adipocytes with TNFα and
various pharmacological inhibitors the method was as
described [23-25]. After serum-starvation for 6 h, 3T3-L1
adipocytes were pretreated with either 50 μM LY294002,
50 μM PD98059, 20 μM SB203580, 100 nM wortmannin,
1  μM rapamycin (Sigma-Aldrich, St. Louis, MO), or
DMSO vehicle for 1 h and then cultured in 10 ng/ml of
TNFα for 16 h in the presence of inhibitors. RNA was puri-
fied using TriZol Reagent (Invitrogen Corp.) according to
manufacturer's instruction. For studies of Tmem182 tran-
script expression in murine tissues, 8 wk old C57BL/6 or
ob/ob male mice were utilized, with all animal treatments
conducted with approval of the University of Toledo
Health Science Campus Institutional Animal Care and
Use Committee.
Real-time PCR analysis was as previously described
[23,24,26]. For this, total RNA was subject to purification
with an RNeasy RNA purification kit with DNase I treat-
ment (Qiagen Corp., Valencia, CA) and 5 μg used for first
strand cDNA synthesis with SuperScript II RNase H-
reverse transcriptase (Invitrogen Corp.) and an oligo(dT)-
22 primer. Real time PCR was conducted with an ABI
7500 Real Time PCR System. Target cDNA levels were ana-
lyzed by SYBR green-based real-time PCR in 25 μl reac-
tions containing 1× SYBR Green PCR Master Mix (Applied
Biosystems, Foster City, CA), 100 nM each forward and
reverse primers, and 10 ng of cDNA. Analyses were per-
formed in triplicate and expression of each gene was nor-
malized against Gapdh transcript level. The cycle
threshold value was generated using ABI PRISM 7500 SDS
software version 1.2 and exported to an Excel spreadsheet
to calculate fold differences. Sequence of PCR primers
used were: Tmem182 (5'-ACACCAATCAGCCACCATCC-
3' and 5'-GCCACGGTAAATAATTGCGGAG-3'); Gapdh
(5'-GGCAAATTCAACGGCACAG-3' and 5'-CGGAGAT-
GATGACCCTTTTG-3'); and Myogenin (5'-GCCATCCAG-
TACATTGAGC-3'and 5'-GTAAGGGAGTGCAGATTGTG-
3'). Primers were designed to span introns.
Properties of Tmem182 gene and sequence
During the characterization and utilization of a new in
vitro model of brown adipogenesis, mBAP-9, we previ-
ously identified ten new genes with increased expression
in mBAP-9 adipocytes vs. preadipocytes (manuscript in
preparation). Of the ten genes identified, the gene found
to exhibit the highest fold upregulation in mBAP-9 adipo-
genesis (45-fold), encoded an uncharacterized novel pre-
dicted transmembrane protein termed Tmem182. Its
transcript expression and regulation, however, was not
further characterized at the time. Tmem182 is represented
by UniGene Mm.334678 [GenBank: NM_001081198]. It
encodes a wholly novel 229 amino acid protein with a cal-
culated molecular mass of 25,845. The protein sequence
of Tmem182 is shown in Figure 1A. The Kyte-Doolittle
analysis of Tmem182 protein sequence identifies four
putative membrane-spanning regions (Figure 1B, and
underlined and bolded in Figure 1A), indicative of an
integral membrane topology. Database analysis (NCBI
Homologene) indicates that Tmem182 homologs are
found in human (90%), dog (87%), rat (87%) chick
(71%), with numbers in parentheses indicating percent
amino acid identity to the murine protein. Homologs are
also present in pig, horse, monkey and zebrafish.
Tissue distribution of Tmem182 transcript expression
We determined transcript expression of Tmem182 in a
panel of murine tissues using real-time PCR. As shown in
Figure 2A, of the tissues examined, subcutaneous WAT is
the most enriched site of transcript expression (p < 0.001),
with expression in muscle, heart and lung at levels from
~10% to ~50% of that in WAT. Lower relative levels of
Tmem182 transcript are found in kidney, spleen, testis,
brain and liver. We also examined Tmem182 transcript
level in brown adipose tissue (BAT) and three distinct
WAT depots, subcutaneous (SC), epididymal (EP) and ret-
roperitoneal (RP), Figure 2B. We find that each of theBMC Research Notes 2008, 1:85 http://www.biomedcentral.com/1756-0500/1/85
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three WAT depots have a similar magnitude of expression
of Tmem182 transcript with from ~10- to ~20-fold higher
levels (p < 0.001) than that found in BAT.
To begin to address the modulation of Tmem182 tran-
script levels in regard to the pathophysiology of adi-
pocytes, we compared transcript expression in BAT and
WAT from wild type C57BL/6 mice and ob/ob mice, the lat-
ter a well-studied murine model of genetic obesity. For
Tmem182 transcript, we find a slight increase (~1.7-fold,
p < 0.001) in ob/ob WAT for the SC depot (Figure 2C). Fur-
thermore, compared to wt BAT, we find a 6.3-fold upreg-
ulation (p < 0.001) of Tmem182 transcript level in ob/ob
vs.  wt BAT, suggestive of a role for dysregulation of
Tmem182 in the obese state (Figure 2C). It would thus
appear that in the ob/ob genetic model, BAT shifts to a level
of Tmem182 transcript expression that is more similar to
that found in WAT.
Differentiation-dependent expression of Tmem182 
transcript in adipogenesis
We originally identified Tmem182 during the characteri-
zation of a new brown adipocyte in vitro cell culture
model, termed mBAP-9, wherein we found Tmem182
transcript to be upregulated 45-fold during the adipogenic
conversion of these cells from preadipocytes to mature
adipocytes (manuscript in preparation). Our tissue
expression studies, however, revealed that although BAT is
a site of expression of Tmem182 transcript, the most dom-
inant site of expression in vivo is WAT. We therefore deter-
mined if Tmem182 transcript evidenced differentiation-
dependent expression in various in vitro models of white
Sequence analysis predicts a transmembrane localization for Tmem182 protein Figure 1
Sequence analysis predicts a transmembrane localization for Tmem182 protein. (A) Amino acid sequence of 
murine Tmem182. The numbers at right indicate amino acid positions. The four putative membrane-spanning regions are 
underlined. (B) Results of Kyte-Doolittle analysis with a window size of 10, indicating 4 putative transmembrane regions. 
Hydrophobicity score is on the y-axis and amino acid residue position on the x-axis.BMC Research Notes 2008, 1:85 http://www.biomedcentral.com/1756-0500/1/85
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Figure 2 (see legend on next page)BMC Research Notes 2008, 1:85 http://www.biomedcentral.com/1756-0500/1/85
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adipogenesis. The best characterized cell culture model of
adipogenesis is 3T3-L1, these cells were developed ~30
years ago [11] and undergo differentiation from preadi-
pocytes to mature white adipocytes following treatment
with the adipogenic agents Dex and MIX. Real-time PCR
analysis indicates that 3T3-L1 adipocytes express ~2500-
fold higher levels of Tmem182 transcript than 3T3-L1
preadipocytes (Figure 3A). The increase in transcript
expression is first noted at day 3, with a 157-fold increase
noted. In addition to the 3T3-L1 model, we examined
Tmem182 transcript expression in two other models of
white adipogenesis. ScAP-23 cells are a cell line estab-
lished in this laboratory derived from preadipocytes
present in murine SC WAT, in contrast to the embryonic
derivation of 3T3-L1 cells. As shown in Figure 3B, adipo-
genesis of ScAP-23 cells leads to a 75-fold increase in lev-
els of Tmem182 transcript. Figure 3C shows that
adipocyte conversion of primary cultures of murine stro-
mal vascular fraction cells from SC WAT, wherein preadi-
pocytes are found, is accompanied by an ~22-fold
increase in Tmem182 transcript. Although we find differ-
ing magnitudes of upregulation of Tmem182 transcript
across the adipogenesis models that we assessed, in all
cases a significant increase in Tmem182 transcript level
accompanies adipocyte conversion.
Regulation of Tmem182 transcript by TNFα
We determined the regulation of Tmem182 transcript fol-
lowing incubation of in vitro differentiated 3T3-L1 white
adipocytes with TNFα. TNFα is a proinflammatory
cytokine central to adipose tissue pathophysiology and
acts to suppress expression of many adipocyte genes; ele-
vated TNFα levels are associated with obesity [27-31].
TNFα treatment of adipocytes promotes lipolysis and ded-
ifferentiation [32-34], with the latter ascribed TNFα-medi-
ated transcriptional downregulation of the key adipocyte
transcription factors PPARγ [35] and C/EBPα [36,37].
Studies of TNFα effects on Tmem182 transcript expres-
sion were carried out using treatment with TNFα alone, or
by treating cells with TNFα after adipocytes had been pre-
treated with pharmacological inhibitors including those
for intracellular signaling pathways with a role in adi-
pocyte gene expression and/or function. For example,
reports indicate a role for p38 MAP kinase in the effects of
TNFα on adipocyte gene expression [38,39] and the TNFα
effects on the transcript expression of the novel adipocyte
lipase ATGL are attenuated by pretreatment with PD-
98059, LY-294002, or rapamycin, suggesting involvement
of the p44/42 MAP kinase, PI 3-kinase, and p70 ribos-
omal protein S6 kinase signals [40]. As shown in Figure 4,
TNFα treatment results in an ~90% decrease (p < 0.005)
in transcript level for Tmem182 transcript. We postulated
that identification of the intracellular signaling path-
way(s) involved in the TNFα-mediated decrease might be
one step towards gaining insights into Tmem182 func-
tion. For example, TNFα might exert its inhibitory effects
by the same intracellular signaling mechanism(s) for a
particular subset of genes that share similar and/or related
functions in adipocytes. However, the data in Figure 4
reveal that none of the tested pharmacological inhibitors
blocked the effects of TNFα, suggesting that TNFα-medi-
ated diminution of Tmem182 transcript expression occurs
via a signaling pathway(s) that is not reliant on p38 MAP
kinase, p44/42 MAP kinase, p70 S6 or PI 3-kinase.
Differentiation-dependent expression of Tmem182 
transcript in myogenesis
The tissue profiling study in Figure 2 indicates that muscle
is also a site of enriched expression of Tmem182 tran-
script. Adipocytes and myocytes are thought to arise in
development from a shared mesenchymal stem cell pre-
cursor [8,41]. The annotation for the GenBank entry
[GenBank:NM_001081198] for Tmem182 indicates it
was among the transcripts identified by Kuninger and
coworkers in a study of novel genes induced during
growth factor-mediated muscle cell survival and differen-
tiation [42]. However, neither the regulation of Tmem182
transcript expression during myogenesis, nor any men-
tion of Tmem182, was in their published report [42]. To
determine if Tmem182 was induced during muscle differ-
White adipose tissue enrichment of Tmem182 and dysregulation in ob/ob adipose tissues Figure 2 (see previous page)
White adipose tissue enrichment of Tmem182 and dysregulation in ob/ob adipose tissues. (A) Tmem182 tran-
script expression in various murine tissues. RNA was harvested from the indicated murine tissues and Tmem182 transcript 
level was analyzed by real-time PCR as described in Methods. Values were normalized to Gapdh expression level and transcript 
expression in lung was set to a value of 1. Statistical analysis was carried out with one-way ANOVA followed by Tukey post-
hoc test. ** indicates p < 0.001 for SC WAT vs. all other tissues. * indicates p < 0.01 for muscle, heart, and lung vs. all other tis-
sues. (B) Tmem182 transcript expression in wild type brown and white adipose tissues and (C) Expression of Tmem182 tran-
script in wild type (wt) vs. ob/ob white and brown adipose tissues. RNA was harvested from subcutaneous (SC) WAT, 
epididymal (EP) WAT and brown adipose tissue (BAT) of wild type (wt) and ob/ob (ob) mice and real-time PCR for Tmem182 
transcript was performed as described in Methods. Values were normalized to Gapdh transcript expression level. Transcript 
expression in BAT was set to a value of 1 for (B) and wt was set to a value of 1 for (C). Statistical analysis was carried out with 
single-factor ANOVA. For (B), * indicates p < 0.001 for SC, EP, and RP vs. BAT. For (C), * indicates p < 0.001 for ob BAT vs. 
wt BAT and for ob SC vs. wt SC.BMC Research Notes 2008, 1:85 http://www.biomedcentral.com/1756-0500/1/85
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entiation we utilized the C2C12 model of in vitro myogen-
esis [43]. As is shown in the left panel of Figure 5,
Tmem182 transcript is markedly upregulated during the
conversion of C2C12 myoblasts to myotubes. A 10-fold
increase (p < 0.001) in transcript level is noted one day
post induction of differentiation and cultures at 7 days
post myogenic induction express ~770 times higher (p <
0.001) levels of Tmem182 transcript compared to the
level in C2C12 day 0 myoblasts. The right panel of Figure
5 shows the expression of transcript for myogenin, a mus-
cle regulatory gene that serves as a marker for myogenesis
[43,44].
Summary
The primary amino acid sequence of Tmem182 predicts
an evolutionarily conserved novel transmembrane pro-
tein. Tmem182 protein sequence lacks homologies with
previously defined protein families and Tmem182 func-
tion is currently unknown. Enrichment of Tmem182 tran-
script in WAT, alteration in obesity, differentiation-
dependent upregulation in adipogenesis and regulation
by TNFα suggests that expression of Tmem182 may be
integral to the adipocyte phenotype. Interestingly,
Tmem182 transcript is also enriched in muscle tissue and
it is markedly upregulated during in vitro myogenesis of
C2C12 myoblasts to myocytes. This suggests Tmem182
may function in cellular pathways shared by adipocytes
and myocytes but not by their respective precursor cell
types. Future studies will further examine the in vitro and
in vivo regulation and the function of Tmem182 in adi-
pocytes and muscle cells.
Tmem182 is a differentiation-dependent gene in white adipo- genesis Figure 3
Tmem182 is a differentiation-dependent gene in 
white adipogenesis. (A) Tmem182 transcript expression 
during a time course of 3T3-L1 differentiation. 3T3-L1 RNA 
was harvested daily at the indicated days preceding (D-1) and 
during differentiation. Tmem182 transcript level was ana-
lyzed by real-time PCR as described in Methods. Values were 
normalized to Gapdh transcript expression level. For D-1, 
D0, D1, and D2, a value of 40 cycles was assigned to calcu-
late a delta Ct value and transcript expression in D-1 sample 
was set to a value of 1. Statistical analysis was carried out 
using one-way ANOVA followed by Tukey post-hoc test; * 
indicates p < 0.001 for D3, D4, D5, D6 and D7 vs. all other 
samples. (B) Tmem182 transcript expression in ScAP-23 
preadipocytes (Pre) and adipocytes (Adi) and (C) Tmem182 
transcript expression in primary murine subcutaneous pread-
ipocytes (Pre) and adipocytes (Adi). RNA was harvested 
from the indicated cultures before and after differentiation 
and Tmem182 transcript level was analyzed by real-time PCR 
as described in Methods. Values were normalized to Gapdh 
transcript expression level and transcript expression in Pre 
set to a value of 1. For (B) and (C), statistical analysis was 
carried out with single-factor ANOVA; * indicates p < 0.001 
for Pre vs. Adi.
TNFα downregulates Tmem182 transcript expression in  3T3-L1 adipocytes Figure 4
TNFα downregulates Tmem182 transcript expres-
sion in 3T3-L1 adipocytes. After serum-starvation for 6 h, 
3T3-L1 adipocytes were incubated with either DMSO vehicle 
(V), 50 μM PD98059 (PD), 20 μM SB20358 (SB), 50 μM 
LY294002 (LY), 100 nM wortmannin (WM), or 1 μM 
rapamycin (Rap) for 1 h and then either treated or untreated 
with 10 ng/ml of TNFα for 16 h. RNA samples were har-
vested and Tmem182 transcript level was analyzed by real-
time PCR as described in Methods. Values were normalized 
to Gapdh transcript expression level and transcript expres-
sion in vehicle alone was set to a value of 1. Statistical analysis 
was carried out using one-way ANOVA followed by Tukey 
post-hoc test; * indicates p < 0.001 for indicated samples vs. 
V alone (first column). Treatment with inhibitors alone failed 
to appreciably alter expression for Tmem182 transcript (data 
not shown).BMC Research Notes 2008, 1:85 http://www.biomedcentral.com/1756-0500/1/85
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